GlassScriptPhysician profile
Joseph D Boss
NPI 1912346388
$19,187.22
in general payments reported to CMS, 2019-2025
21 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
See the full distribution for Uveitis and Ocular Inflammatory Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $5,507 · 2021: $2,337 · 2022: $1,647 · 2023: $4,906 · 2024: $3,509 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,253.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $7,361.18 | 2020-2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $5,455.40 | 2019-2021 | |
| Eyepoint US, INC. | $1,762.10 | 2019-2023 | |
| US Retina LLC | $1,516.78 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $733.06 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $604.05 | 2022-2025 | Xipere, Stellaris |
| Apellis Pharmaceuticals, INC. | $364.85 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $246.50 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Allergan, INC. | $173.23 | 2019-2021 | |
| Genentech USA, INC. | $167.36 | 2021-2025 | Vabysmo |
| Coherus Oncology, INC. | $147.54 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $137.07 | 2019 | |
| Biogen, INC. | $114.14 | 2022-2024 | Byooviz |
| Abbvie INC. | $89.72 | 2019-2025 | Durysta |
| Mallinckrodt Hospital Products INC. | $61.65 | 2023-2024 | Acthar |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.74 | 2024-2025 | Tepezza |
| Mallinckrodt Enterprises LLC | $55.45 | 2019 | |
| Astellas Pharma US INC | $55.33 | 2024-2025 | Izervay |
| Harrow Eye, LLC | $35.98 | 2025 | Triesence |
| Biotissue Holdings INC. | $30.60 | 2021-2022 | |
| Dompe US, INC. | $15.49 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$68,674.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Boss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.